Abror Mukhitdinov1, Nemat Olimov1, Shirinkhan Olimova1.
Abstract
OBJECTIVES: Chronic suppurative otitis media (CSOM) is a serious disease with the presence of bacterial infection in the middle ear. Worldwide, 1% to 46% of the population living in developed and developing countries have CSOM, about 65-330 million people, 60% of whom have significant hearing loss. The study of the wound healing efficacy and tolerability of the drug MEKRITEN (garlic extract liquid) was performed to identify the possibility of issuing recommendations for the drug for clinical use in the Republic of Uzbekistan.
MATERIALS AND METHODS: The main group of patients, who received the study drug, consisted of 30 patients; the group of patients who received the comparison drug comprised 20 patients. Patients of the main group (30 persons) were given 'garlic extract liquid,' which was developed by the Tashkent Pharmaceutical Institute, given as 2 drops twice per day for 10 days in the external auditory canal. Patients in the comparison group (20 people) took other drugs (0.25% solution of levomycetin) in a similar way. Patients were examined and observed carefully to determine the severity of symptoms such as pain, secretion (in points), and clinical analyses were performed including general blood analysis, and urine. In addition, the researchers performed biochemical (ALT, AST, bilirubin), instrumental (ultrasound of the liver), and special (biopsy of fibrous tissue of echinococcal capsules) analyses.
RESULTS: The average rating of the tolerability and effectiveness in the points for MEKRITEN made portability of 4.97 points, and the effectiveness was 4.77 points, and for 0.25% levomycetin solution, they were 4.8 and 3.35 points, respectively. While receiving MEKRITEN, no adverse effects and allergic reactions were observed. No criteria for treatment cessation were observed (adverse effects, ineffective treatment, poor adherence to protocol, and refusal to continue) thus the study was not stopped in any patients.
CONCLUSION: Local therapy with the drug MEKRITEN in patients with CSOM is more effective than local application of 0.25% levomycetin solution. Local therapy with MEKRITEN in the treatment of CSOM leads to faster termination of otorrhoea and is accompanied by fewer adverse drug reactions. ©Copyright 2018 Turk J Pharm Sci, Published by Galenos Publishing House.
OBJECTIVES: Chronic suppurative otitis media (CSOM) is a serious disease with the presence of bacterial infection in the middle ear. Worldwide, 1% to 46% of the population living in developed and developing countries have CSOM, about 65-330 million people, 60% of whom have significant hearing loss. The study of the wound healing efficacy and tolerability of the drug MEKRITEN (garlic extract liquid) was performed to identify the possibility of issuing recommendations for the drug for clinical use in the Republic of Uzbekistan.
MATERIALS AND METHODS: The main group of patients, who received the study drug, consisted of 30 patients; the group of patients who received the comparison drug comprised 20 patients. Patients of the main group (30 persons) were given 'garlic extract liquid,' which was developed by the Tashkent Pharmaceutical Institute, given as 2 drops twice per day for 10 days in the external auditory canal. Patients in the comparison group (20 people) took other drugs (0.25% solution of levomycetin) in a similar way. Patients were examined and observed carefully to determine the severity of symptoms such as pain, secretion (in points), and clinical analyses were performed including general blood analysis, and urine. In addition, the researchers performed biochemical (ALT, AST, bilirubin), instrumental (ultrasound of the liver), and special (biopsy of fibrous tissue of echinococcal capsules) analyses.
RESULTS: The average rating of the tolerability and effectiveness in the points for MEKRITEN made portability of 4.97 points, and the effectiveness was 4.77 points, and for 0.25% levomycetin solution, they were 4.8 and 3.35 points, respectively. While receiving MEKRITEN, no adverse effects and allergic reactions were observed. No criteria for treatment cessation were observed (adverse effects, ineffective treatment, poor adherence to protocol, and refusal to continue) thus the study was not stopped in any patients.
CONCLUSION: Local therapy with the drug MEKRITEN in patients with CSOM is more effective than local application of 0.25% levomycetin solution. Local therapy with MEKRITEN in the treatment of CSOM leads to faster termination of otorrhoea and is accompanied by fewer adverse drug reactions. ©Copyright 2018 Turk J Pharm Sci, Published by Galenos Publishing House.
Entities:
Keywords:
MEKRITEN; chronic suppurative otitis media; garlic extract liquid; levomycetin
Year: 2018
PMID： 32454659 PMCID： PMC7228021 DOI： 10.4274/tjps.52824
Source DB: PubMed Journal: Turk J Pharm Sci ISSN： 1304-530X